Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy - Concepedia

Concepedia

Publication | Open Access

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

DOI Full Paper Access

211

Citations

15

References

2011

Year

Phuong K. Morrow, Gerburg M. Wulf, Joe Ensor, Daniel J. Booser, Julia Ann Moore, P. R. Flores, Yan Xiong, Siyuan Zhang, Ian E. Krop, Eric P. Winer,

Journal of Clinical Oncology

Abstract

Inhibition of mTOR results in clinical benefit and disease response in patients with trastuzumab-resistant HER2-overexpressing MBC.

References

	Year	Citations

Page 1